December 5, 2025Advances in HematologyOpen Access

Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center

View Full Paper

Ask AI

Bookmark

Authors

KLKevin H. Lin LHLynn Huynh XYXiaoqin Yang

Discussion

Member takes

Implication

Analysis of therapies post-BTKi treatment discontinuation reveals survival challenges in chronic lymphocytic leukemia patients, suggesting urgent treatment needs.

Key Points

Over half of chronic lymphocytic leukemia patients received therapies post-BTKi treatment discontinuation, highlighting clinical outcomes.
Median progression-free survival was 3.2 years and median overall survival was 8.9 years in those treated with BTKi.
Retrospective chart review included 104 adult patients treated with covalent BTKi from July 2011 to April 2019, noting significant findings.
Findings point to the strong unmet need for effective new strategies for treating relapsed or refractory patients.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/693231368e51979591dceade https://doi.org/10.1155/ah/7492594

View Full Paper

Ask AI

Bookmark

Implication

Analysis of therapies post-BTKi treatment discontinuation reveals survival challenges in chronic lymphocytic leukemia patients, suggesting urgent treatment needs.

Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider